|
1
|
Graham GG, Punt J, Arora M, Day RO, Doogue
MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick
CM, et al: Clinical pharmacokinetics of metformin. Clin
Pharmacokinet. 50:81–98. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Apostolova N, Iannantuoni F, Gruevska A,
Muntane J, Rocha M and Victor VM: Mechanisms of action of metformin
in type 2 diabetes: Effects on mitochondria and
leukocyte-endothelium interactions. Redox Biol. 34:1015172020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rena G, Hardie DG and Pearson ER: The
mechanisms of action of metformin. Diabetologia. 60:1577–1585.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma T, Tian X, Zhang B, Li M, Wang Y, Yang
C, Wu J, Wei X, Qu Q, Yu Y, et al: Low-dose metformin targets the
lysosomal AMPK pathway through PEN2. Nature. 603:159–165. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Viollet B, Guigas B, Sanz Garcia N,
Leclerc J, Foretz M and Andreelli F: Cellular and molecular
mechanisms of metformin: An overview. Clin Sci (Lond). 122:253–270.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: A cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Landman GW, Kleefstra N, van Hateren KJ,
Groenier KH, Gans RO and Bilo HJ: Metformin associated with lower
cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care.
33:322–326. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shaw RJ, Bardeesy N, Manning BD, Lopez L,
Kosmatka M, DePinho RA and Cantley LC: The LKB1 tumor suppressor
negatively regulates mTOR signaling. Cancer Cell. 6:91–99. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tomic T, Botton T, Cerezo M, Robert G,
Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder
JM, et al: Metformin inhibits melanoma development through
autophagy and apoptosis mechanisms. Cell Death Dis. 2:e1992011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taubes G: Cancer research. Cancer
prevention with a diabetes pill? Science. 335:292012.PubMed/NCBI
|
|
11
|
Tian RH, Zhang YG, Wu Z, Liu X, Yang JW
and Ji HL: Effects of metformin on survival outcomes of lung cancer
patients with type 2 diabetes mellitus: A meta-analysis. Clin
Transl Oncol. 18:641–649. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin JJ, Gallagher EJ, Sigel K, Mhango G,
Galsky MD, Smith CB, LeRoith D and Wisnivesky JP: Survival of
patients with stage IV lung cancer with diabetes treated with
metformin. Am J Respir Crit Care Med. 191:448–454. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo W, Kuang Y, Wu J, Wen D, Zhou A, Liao
Y, Song H, Xu D, Wang T, Jing B, et al: Hexokinase 2 depletion
confers sensitization to metformin and inhibits glycolysis in lung
squamous cell carcinoma. Front Oncol. 10:522020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang J, Gao Q, Wang D, Wang Z and Hu C:
Metformin inhibits growth of lung adenocarcinoma cells by inducing
apoptosis via the mitochondria-mediated pathway. Oncol Lett.
10:1343–1349. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Teixeira SF, Guimarães Idos S, Madeira KP,
Daltoé RD, Silva IV and Rangel LB: Metformin synergistically
enhances antiproliferative effects of cisplatin and etoposide in
NCI-H460 human lung cancer cells. J Bras Pneumol. 39:644–649. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ashinuma H, Takiguchi Y, Kitazono S,
Kitazono-Saitoh M, Kitamura A, Chiba T, Tada Y, Kurosu K, Sakaida
E, Sekine I, et al: Antiproliferative action of metformin in human
lung cancer cell lines. Oncol Rep. 28:8–14. 2012.PubMed/NCBI
|
|
17
|
Tan BX, Yao WX, Ge J, Peng XC, Du XB,
Zhang R, Yao B, Xie K, Li LH, Dong H, et al: Prognostic influence
of metformin as first-line chemotherapy for advanced nonsmall cell
lung cancer in patients with type 2 diabetes. Cancer.
117:5103–5111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stevens RJ, Ali R, Bankhead CR, Bethel MA,
Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst JA,
et al: Cancer outcomes and all-cause mortality in adults allocated
to metformin: Systematic review and collaborative meta-analysis of
randomised clinical trials. Diabetologia. 55:2593–2603. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ece H, Cigdem E, Yuksel K, Ahmet D, Hakan
E and Oktay TM: Use of oral antidiabetic drugs (metformin and
pioglitazone) in diabetic patients with breast cancer: How does it
effect serum Hif-1 alpha and 8Ohdg levels? Asian Pac J Cancer Prev.
13:5143–5148. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Berbée JF, Boon MR, Khedoe PP, Bartelt A,
Schlein C, Worthmann A, Kooijman S, Hoeke G, Mol IM, John C, et al:
Brown fat activation reduces hypercholesterolaemia and protects
from atherosclerosis development. Nat Commun. 6:63562015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hardie DG and Alessi DR: LKB1 and AMPK and
the cancer-metabolism link-ten years after. BMC Biol. 11:362013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koivunen JP, Kim J, Lee J, Rogers AM, Park
JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, et al:
Mutations in the LKB1 tumour suppressor are frequently detected in
tumours from Caucasian but not Asian lung cancer patients. Br J
Cancer. 99:245–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han D, Li SJ, Zhu YT, Liu L and Li MX:
LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.
Asian Pac J Cancer Prev. 14:4033–4039. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gwinn DM, Shackelford DB, Egan DF,
Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ: AMPK
phosphorylation of raptor mediates a metabolic checkpoint. Mol
Cell. 30:214–226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rabiee A, Krüger M, Ardenkjær-Larsen J,
Kahn CR and Emanuelli B: Distinct signalling properties of insulin
receptor substrate (IRS)-1 and IRS-2 in mediating insulin/IGF-1
action. Cell Signal. 47:1–15. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang X and Proud CG: The mTOR pathway in
the control of protein synthesis. Physiology (Bethesda).
21:362–369. 2006.PubMed/NCBI
|
|
28
|
Morita M, Gravel SP, Hulea L, Larsson O,
Pollak M, St-Pierre J and Topisirovic I: mTOR coordinates protein
synthesis, mitochondrial activity and proliferation. Cell Cycle.
14:473–480. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ren GF, Xiao LL, Ma XJ, Yan YS and Jiao
PF: Metformin decreases insulin resistance in type 1 diabetes
through regulating p53 and RAP2A in vitro and in vivo. Drug Des
Devel Ther. 14:2381–2392. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Storozhuk Y, Hopmans SN, Sanli T, Barron
C, Tsiani E, Cutz JC, Pond G, Wright J, Singh G and Tsakiridis T:
Metformin inhibits growth and enhances radiation response of
non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J
Cancer. 108:2021–2032. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blagih J, Buck MD and Vousden KH: p53,
cancer and the immune response. J Cell Sci. 133:jcs2374532020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu G, Pei F, Yang F, Li L, Amin AD, Liu
S, Buchan JR and Cho WC: Role of autophagy and apoptosis in
non-small-cell lung cancer. Int J Mol Sci. 18:3672017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bykov VJN, Eriksson SE, Bianchi J and
Wiman KG: Targeting mutant p53 for efficient cancer therapy. Nat
Rev Cancer. 18:89–102. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Buzzai M, Jones RG, Amaravadi RK, Lum JJ,
DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic
treatment with the antidiabetic drug metformin selectively impairs
p53-deficient tumor cell growth. Cancer Res. 67:6745–6752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dogan Turacli I, Candar T, Yuksel BE and
Demirtas S: Role of metformin on base excision repair pathway in
p53 wild-type H2009 and HepG2 cancer cells. Hum Exp Toxicol.
37:909–919. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ben Sahra I, Regazzetti C, Robert G,
Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF,
Giorgetti-Peraldi S and Bost F: Metformin, independent of AMPK,
induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer
Res. 71:4366–4372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Blandino G, Valerio M, Cioce M, Mori F,
Casadei L, Pulito C, Sacconi A, Biagioni F, Cortese G, Galanti S,
et al: Metformin elicits anticancer effects through the sequential
modulation of DICER and c-MYC. Nat Commun. 3:8652012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Szczyrek M, Grenda A, Kuźnar-Kamińska B,
Krawczyk P, Sawicki M, Batura-Gabryel H, Mlak R, Szudy-Szczyrek A,
Krajka T, Krajka A, et al: Methylation of DROSHA and DICER as a
biomarker for the detection of lung cancer. Cancers (Basel).
13:61392021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pradhan AK, Bhoopathi P, Talukdar S,
Scheunemann D, Sarkar D, Cavenee WK, Das SK, Emdad L and Fisher PB:
MDA-7/IL-24 regulates the miRNA processing enzyme DICER through
downregulation of MITF. Proc Natl Acad Sci USA. 116:5687–5692.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Prodromaki E, Korpetinou A, Giannopoulou
E, Vlotinou E, Chatziathanasiadou Μ, Papachristou NI, Scopa CD,
Papadaki H, Kalofonos HP and Papachristou DJ: Expression of the
microRNA regulators drosha, dicer and Ago2 in non-small cell lung
carcinomas. Cell Oncol (Dordr). 38:307–317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen JC, Su YH, Chiu CF, Chang YW, Yu YH,
Tseng CF, Chen HA and Su JL: Suppression of Dicer increases
sensitivity to gefitinib in human lung cancer cells. Ann Surg
Oncol. 21 (Suppl 4):S555–563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li C, Chen L, Song W, Peng B, Zhu J and
Fang L: DICER activates autophagy and promotes cisplatin resistance
in non-small cell lung cancer by binding with let-7i-5p. Acta
Histochem. 123:1517882021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim J, Kundu M, Viollet B and Guan KL:
AMPK and mTOR regulate autophagy through direct phosphorylation of
Ulk1. Nat Cell Biol. 13:132–141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu M, Zhang Z, Wang H, Chen X and Jin C:
Activation of AMPK by metformin promotes renal cancer cell
proliferation under glucose deprivation through its interaction
with PKM2. Int J Biol Sci. 15:617–627. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Volm M and Koomägi R: Hypoxia-inducible
factor (HIF-1) and its relationship to apoptosis and proliferation
in lung cancer. Anticancer Res. 20:1527–1533. 2000.PubMed/NCBI
|
|
46
|
Yang SL, Ren QG, Wen L and Hu JL:
Clinicopathological and prognostic significance of
hypoxia-inducible factor-1 alpha in lung cancer: A systematic
review with meta-analysis. J Huazhong Univ Sci Technolog Med Sci.
36:321–327. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang J, Wang Q, Wang Q, Guo P, Wang Y,
Xing Y, Zhang M, Liu F and Zeng Q: Chrysophanol exhibits
anti-cancer activities in lung cancer cell through regulating
ROS/HIF-1a/VEGF signaling pathway. Naunyn Schmiedebergs Arch
Pharmacol. 393:469–480. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Akakura N, Kobayashi M, Horiuchi I, Suzuki
A, Wang J, Chen J, Niizeki H, Kawamura K, Hosokawa M and Asaka M:
Constitutive expression of hypoxia-inducible factor-1alpha renders
pancreatic cancer cells resistant to apoptosis induced by hypoxia
and nutrient deprivation. Cancer Res. 61:6548–6554. 2001.PubMed/NCBI
|
|
49
|
Pineda CT, Ramanathan S, Fon Tacer K, Weon
JL, Potts MB, Ou YH, White MA and Potts PR: Degradation of AMPK by
a cancer-specific ubiquitin ligase. Cell. 160:715–728. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fürstenberger G and Senn HJ: Insulin-like
growth factors and cancer. Lancet Oncol. 3:298–302. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Favoni RE, de Cupis A, Ravera F, Cantoni
C, Pirani P, Ardizzoni A, Noonan D and Biassoni R: Expression and
function of the insulin-like growth factor I system in human
non-small-cell lung cancer and normal lung cell lines. Int J
Cancer. 56:858–866. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tseng SC, Huang YC, Chen HJ, Chiu HC,
Huang YJ, Wo TY, Weng SH and Lin YW: Metformin-mediated
downregulation of p38 mitogen-activated protein kinase-dependent
excision repair cross-complementing 1 decreases DNA repair capacity
and sensitizes human lung cancer cells to paclitaxel. Biochem
Pharmacol. 85:583–594. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kuribayashi A, Kataoka K, Kurabayashi T
and Miura M: Evidence that basal activity, but not transactivation,
of the epidermal growth factor receptor tyrosine kinase is required
for Insulin-like growth factor I-induced activation of
extracellular signal-regulated kinase in oral carcinoma cells.
Endocrinology. 145:4976–4984. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Cao H, Dong W, Qu X, Shen H, Xu J, Zhu L,
Liu Q and Du J: Metformin enhances the therapy effects of
Anti-IGF-1R mAb figitumumab to NSCLC. Sci Rep. 6:310722016.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Pernicova I and Korbonits M:
Metformin-mode of action and clinical implications for diabetes and
cancer. Nat Rev Endocrinol. 10:143–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Fumarola C, Bonelli MA, Petronini PG and
Alfieri RR: Targeting PI3K/AKT/mTOR pathway in non small cell lung
cancer. Biochem Pharmacol. 90:197–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Heavey S, O'Byrne KJ and Gately K:
Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.
Cancer Treat Rev. 40:445–456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Granville CA, Memmott RM, Balogh A,
Mariotti J, Kawabata S, Han W, Lopiccolo J, Foley J, Liewehr DJ,
Steinberg SM, et al: A central role for Foxp3+ regulatory T cells
in K-Ras-driven lung tumorigenesis. PLoS One. 4:e50612009.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zou W: Regulatory T cells, tumour immunity
and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Memmott RM, Mercado JR, Maier CR, Kawabata
S, Fox SD and Dennis PA: Metformin prevents tobacco
carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila).
3:1066–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kalender A, Selvaraj A, Kim SY, Gulati P,
Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, et
al: Metformin, independent of AMPK, inhibits mTORC1 in a rag
GTPase-dependent manner. Cell Metab. 11:390–401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Efeyan A, Zoncu R, Chang S, Gumper I,
Snitkin H, Wolfson RL, Kirak O, Sabatini DD and Sabatini DM:
Regulation of mTORC1 by the Rag GTPases is necessary for neonatal
autophagy and survival. Nature. 493:679–683. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bar-Peled L, Schweitzer LD, Zoncu R and
Sabatini DM: Ragulator is a GEF for the rag GTPases that signal
amino acid levels to mTORC1. Cell. 150:1196–1208. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kim J and Kim E: Rag GTPase in amino acid
signaling. Amino Acids. 48:915–928. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Liu Y, He C and Huang X: Metformin
partially reverses the carboplatin-resistance in NSCLC by
inhibiting glucose metabolism. Oncotarget. 8:75206–75216. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Salani B, Del Rio A, Marini C, Sambuceti
G, Cordera R and Maggi D: Metformin, cancer and glucose metabolism.
Endocr Relat Cancer. 21:R461–R471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Schuurbiers OC, Meijer TW, Kaanders JH,
Looijen-Salamon MG, de Geus-Oei LF, van der Drift MA, van der
Heijden EH, Oyen WJ, Visser EP, Span PN, et al: Glucose metabolism
in NSCLC is histology-specific and diverges the prognostic
potential of 18FDG-PET for adenocarcinoma and squamous cell
carcinoma. J Thorac Oncol. 9:1485–1493. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Lee Y, Joo J, Lee YJ, Lee EK, Park S, Kim
TS, Lee SH, Kim SY, Wie GA, Park M, et al: Randomized phase II
study of Platinum-based chemotherapy plus controlled diet with or
without metformin in patients with advanced Non-small cell lung
cancer. Lung Cancer. 151:8–15. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chun SG, Liao Z, Jeter MD, Chang JY, Lin
SH, Komaki RU, Guerrero TM, Mayo RC, Korah BM, Koshy SM, et al:
Metabolic responses to metformin in inoperable early-stage
non-small cell lung cancer treated with stereotactic radiotherapy:
Results of a randomized Phase II clinical trial. Am J Clin Oncol.
43:231–235. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
O JH, Lodge MA and Wahl RL: Practical
PERCIST: A Simplified Guide to PET response criteria in solid
tumors 1.0. Radiology. 280:576–584. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Goodwin PJ, Ligibel JA and Stambolic V:
Metformin in breast cancer: Time for action. J Clin Oncol.
27:3271–3273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Pollak MN: Investigating metformin for
cancer prevention and treatment: The end of the beginning. Cancer
Discov. 2:778–790. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Wheaton WW, Weinberg SE, Hamanaka RB,
Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM,
Budigner GS, et al: Metformin inhibits mitochondrial complex I of
cancer cells to reduce tumorigenesis. Elife. 3:e022422014.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Andrzejewski S, Gravel SP, Pollak M and
St-Pierre J: Metformin directly acts on mitochondria to alter
cellular bioenergetics. Cancer Metab. 2:122014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Algire C, Moiseeva O, Deschênes-Simard X,
Amrein L, Petruccelli L, Birman E, Viollet B, Ferbeyre G and Pollak
MN: Metformin reduces endogenous reactive oxygen species and
associated DNA damage. Cancer Prev Res (Phila). 5:536–543. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Boyle KA, Van Wickle J, Hill RB, Marchese
A, Kalyanaraman B and Dwinell MB: Mitochondria-targeted drugs
stimulate mitophagy and abrogate colon cancer cell proliferation. J
Biol Chem. 293:14891–14904. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Logie L, Harthill J, Patel K, Bacon S,
Hamilton DL, Macrae K, McDougall G, Wang HH, Xue L, Jiang H, et al:
Cellular responses to the metal-binding properties of metformin.
Diabetes. 61:1423–1433. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Izzotti A, Balansky R, D'Agostini F,
Longobardi M, Cartiglia C, Micale RT, La Maestra S, Camoirano A,
Ganchev G, Iltcheva M, et al: Modulation by metformin of molecular
and histopathological alterations in the lung of cigarette
Smoke-exposed mice. Cancer Med. 3:719–730. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk-database: Prediction of possible miRNA binding sites by
‘Walking’ the genes of three genomes. J Biomed Inform. 44:839–847.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Bost F, Ben-Sahra I and Tanti JF:
Prevention of mutagenesis: New potential mechanisms of metformin
action in neoplastic cells. Cancer Prev Res (Phila). 5:503–506.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhang B, Liu T, Wu T, Wang Z, Rao Z and
Gao J: microRNA-137 functions as a tumor suppressor in human
non-small cell lung cancer by targeting SLC22A18. Int J Biol
Macromol. 74:111–118. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Kefas B, Godlewski J, Comeau L, Li Y,
Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, et
al: microRNA-7 inhibits the epidermal growth factor receptor and
the Akt pathway and is down-regulated in glioblastoma. Cancer Res.
68:3566–3572. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhao X, Dou W, He L, Liang S, Tie J, Liu
C, Li T, Lu Y, Mo P, Shi Y, et al: MicroRNA-7 functions as an
anti-metastatic microRNA in gastric cancer by targeting
Insulin-like growth Factor-1 receptor. Oncogene. 32:1363–1372.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Dong J, Peng H, Yang X, Wu W, Zhao Y, Chen
D, Chen L and Liu J: Metformin mediated microRNA-7 upregulation
inhibits growth, migration, and invasion of non-small cell lung
cancer A549 cells. Anticancer Drugs. 31:345–352. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Jin D, Guo J, Wu Y, Chen W, Du J, Yang L,
Wang X, Gong K, Dai J, Miao S, et al: Metformin-repressed
miR-381-YAP-snail axis activity disrupts NSCLC growth and
metastasis. J Exp Clin Cancer Res. 39:62020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Pearce EL, Walsh MC, Cejas PJ, Harms GM,
Shen H, Wang LS, Jones RG and Choi Y: Enhancing CD8 T-cell memory
by modulating fatty acid metabolism. Nature. 460:103–107. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Eikawa S, Nishida M, Mizukami S, Yamazaki
C, Nakayama E and Udono H: Immune-mediated antitumor effect by type
2 diabetes drug, metformin. Proc Natl Acad Sci USA. 112:1809–1814.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zhao D, Long XD, Lu TF, Wang T, Zhang WW,
Liu YX, Cui XL, Dai HJ, Xue F and Xia Q: Metformin decreases IL-22
secretion to suppress tumor growth in an orthotopic mouse model of
hepatocellular carcinoma. Int J Cancer. 136:2556–2565. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Justus CR, Sanderlin EJ and Yang LV:
Molecular connections between cancer cell metabolism and the tumor
microenvironment. Int J Mol Sci. 16:11055–11086. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Scharping NE, Menk AV, Whetstone RD, Zeng
X and Delgoffe GM: Efficacy of PD-1 blockade is potentiated by
metformin-induced reduction of tumor hypoxia. Cancer Immunol Res.
5:9–16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Lee BB, Kim Y, Kim D, Cho EY, Han J, Kim
HK, Shim YM and Kim DH: Metformin and tenovin-6 synergistically
induces apoptosis through LKB1-independent SIRT1 Down-regulation in
non-small cell lung cancer cells. J Cell Mol Med. 23:2872–2889.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zhou X, Liu S, Lin X, Xu L, Mao X, Liu J,
Zhang Z, Jiang W and Zhou H: Metformin inhibit lung cancer cell
growth and invasion in vitro as well as tumor formation in vivo
partially by activating PP2A. Med Sci Monit. 25:836–846. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Moroishi T, Hansen CG and Guan KL: The
emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 15:73–79.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Jin D, Guo J, Wang D, Wu Y, Wang X, Gao Y,
Shao C, Xu X and Tan S: The antineoplastic drug metformin
downregulates YAP by interfering with IRF-1 binding to the YAP
promoter in NSCLC. EBioMedicine. 37:188–204. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Luo Z, Chen W, Wu W, Luo W, Zhu T, Guo G,
Zhang L, Wang C, Li M and Shi S: Metformin promotes survivin
degradation through AMPK/PKA/GSK-3β-axis in non-small cell lung
cancer. J Cell Biochem. Feb 21–2019.doi: 10.1002/jcb.28470 (Epub
ahead of print). View Article : Google Scholar
|
|
96
|
Salani B, Maffioli S, Hamoudane M, Parodi
A, Ravera S, Passalacqua M, Alama A, Nhiri M, Cordera R and Maggi
D: Caveolin-1 is essential for metformin inhibitory effect on IGF1
action in Non-small-cell lung cancer cells. FASEB J. 26:788–798.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Vazquez-Martin A, Oliveras-Ferraros C,
Cufí S, Martin-Castillo B and Menendez JA: Metformin activates an
ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA Damage-like
response. Cell Cycle. 10:1499–1501. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wu N, Gu C, Gu H, Hu H, Han Y and Li Q:
Metformin induces apoptosis of lung cancer cells through activating
JNK/p38 MAPK pathway and GADD153. Neoplasma. 58:482–490. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Iliopoulos D, Hirsch HA and Struhl K:
Metformin decreases the dose of chemotherapy for prolonging tumor
remission in mouse xenografts involving multiple cancer cell types.
Cancer Res. 71:3196–3201. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Parikh AB, Kozuch P, Rohs N, Becker DJ and
Levy BP: Metformin as a repurposed therapy in advanced Non-small
cell lung cancer (NSCLC): Results of a phase II trial. Invest New
Drugs. 35:813–819. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Marrone KA, Zhou X, Forde PM, Purtell M,
Brahmer JR, Hann CL, Kelly RJ, Coleman B, Gabrielson E, Rosner GL,
et al: A Randomized Phase II study of metformin plus
Paclitaxel/Carboplatin/Bevacizumab in patients with
Chemotherapy-Naïve advanced or metastatic nonsquamous non-small
cell lung cancer. Oncologist. 23:859–865. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Parikh AB, Marrone KA, Becker DJ, Brahmer
JR, Ettinger DS and Levy BP: A pooled analysis of two phase II
trials evaluating metformin plus platinum-based chemotherapy in
advanced non-small cell lung cancer. Cancer Treat Res Commun.
20:1001502019. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Sayed R, Saad AS, El Wakeel L, Elkholy E
and Badary O: Metformin addition to chemotherapy in stage IV
non-small cell lung cancer: An open label randomized controlled
study. Asian Pac J Cancer Prev. 16:6621–6626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW,
Su WP, Chen HH and Su WC: Metformin enhances cisplatin cytotoxicity
by suppressing signal transducer and activator of transcription-3
activity independently of the liver kinase B1-AMP-activated protein
kinase pathway. Am J Respir Cell Mol Biol. 49:241–250. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Weerasinghe P, Garcia GE, Zhu Q, Yuan P,
Feng L, Mao L and Jing N: Inhibition of Stat3 activation and tumor
growth suppression of non-small cell lung cancer by G-quartet
oligonucleotides. Int J Oncol. 31:129–136. 2007.PubMed/NCBI
|
|
106
|
Chiang GG and Abraham RT: Targeting the
mTOR signaling network in cancer. Trends Mol Med. 13:433–442. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wang Y, Lin B, Wu J, Zhang H and Wu B:
Metformin inhibits the proliferation of A549/CDDP cells by
activating p38 mitogen-activated protein kinase. Oncol Lett.
8:1269–1274. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Wang J, Xia S and Zhu Z: Synergistic
effect of phenformin in non-small cell lung cancer (NSCLC) ionizing
radiation treatment. Cell Biochem Biophys. 71:513–518. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Koritzinsky M: Metformin: A novel
biological modifier of tumor response to radiation therapy. Int J
Radiat Oncol Biol Phys. 93:454–464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Bitterman PB and Polunovsky VA:
eIF4E-mediated translational control of cancer incidence. Biochim
Biophys Acta. 1849:774–780. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Chen B, Zhang B, Xia L, Zhang J, Chen Y,
Hu Q and Zhu C: Knockdown of eukaryotic translation initiation
factor 4E suppresses cell growth and invasion, and induces
apoptosis and cell cycle arrest in a human lung adenocarcinoma cell
line. Mol Med Rep. 12:7971–7978. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Sanli T, Rashid A, Liu C, Harding S,
Bristow RG, Cutz JC, Singh G, Wright J and Tsakiridis T: Ionizing
radiation activates AMP-activated kinase (AMPK): A target for
radiosensitization of human cancer cells. Int J Radiat Oncol Biol
Phys. 78:221–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Muaddi H, Chowdhury S, Vellanki R, Zamiara
P and Koritzinsky M: Contributions of AMPK and p53 dependent
signaling to radiation response in the presence of metformin.
Radiother Oncol. 108:446–450. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Barker HE, Paget JT, Khan AA and
Harrington KJ: The tumour microenvironment after radiotherapy:
Mechanisms of resistance and recurrence. Nat Rev Cancer.
15:409–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Levy A, Nigro G, Sansonetti PJ and Deutsch
E: Candidate immune biomarkers for radioimmunotherapy. Biochim
Biophys Acta Rev Cancer. 1868:58–68. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Levy A, Bardet E, Lacas B, Pignon JP, Adam
J, Lacroix L, Artignan X, Verrelle P and Le Péchoux C: A phase II
Open-label multicenter study of gefitinib in combination with
irradiation followed by chemotherapy in patients with inoperable
stage III non-small cell lung cancer. Oncotarget. 8:15924–15933.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Twyman-Saint Victor C, Rech AJ, Maity A,
Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi
PM, et al: Radiation and dual checkpoint blockade activate
non-redundant immune mechanisms in cancer. Nature. 520:373–377.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Tokito T, Azuma K, Kawahara A, Ishii H,
Yamada K, Matsuo N, Kinoshita T, Mizukami N, Ono H, Kage M, et al:
Predictive relevance of PD-L1 expression combined with CD8+ TIL
density in stage III non-small cell lung cancer patients receiving
concurrent chemoradiotherapy. Eur J Cancer. 55:7–14. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Song CW, Lee H, Dings RP, Williams B,
Powers J, Santos TD, Choi BH and Park HJ: Metformin kills and
radiosensitizes cancer cells and preferentially kills cancer stem
cells. Sci Rep. 2:3622012. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Moncharmont C, Levy A, Gilormini M,
Bertrand G, Chargari C, Alphonse G, Ardail D, Rodriguez-Lafrasse C
and Magné N: Targeting a cornerstone of radiation resistance:
Cancer stem cell. Cancer Lett. 322:139–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Wink KC, Belderbos JS, Dieleman EM, Rossi
M, Rasch CR, Damhuis RA, Houben RM and Troost EG: Improved
progression free survival for patients with diabetes and locally
advanced non-small cell lung cancer (NSCLC) using metformin during
concurrent chemoradiotherapy. Radiother Oncol. 118:453–459. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Ko JC, Chiu HC, Wo TY, Huang YJ, Tseng SC,
Huang YC, Chen HJ, Syu JJ, Chen CY, Jian YT, et al: Inhibition of
p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin
enhances gefitinib-induced cytotoxicity in human squamous lung
cancer cells. Lung Cancer. 82:397–406. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Chen H, Yao W, Chu Q, Han R, Wang Y, Sun
J, Wang D, Wang Y, Cao M and He Y: Synergistic effects of metformin
in combination with EGFR-TKI in the treatment of patients with
advanced non-small cell lung cancer and type 2 diabetes. Cancer
Lett. 369:97–102. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Li KL, Li L, Zhang P, Kang J, Wang YB,
Chen HY and He Y: A multicenter Double-blind Phase II study of
metformin with gefitinib as First-Line therapy of locally advanced
non-small-cell lung cancer. Clin Lung Cancer. 18:340–343. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Nguyen GH, Murph MM and Chang JY: Cancer
stem cell radioresistance and enrichment: Where frontline radiation
therapy may fail in lung and esophageal cancers. Cancers (Basel).
3:1232–1252. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Morgillo F, Sasso FC, Della Corte CM,
Vitagliano D, D'Aiuto E, Troiani T, Martinelli E, De Vita F,
Orditura M, De Palma R, et al: Synergistic effects of metformin
treatment in combination with gefitinib, a selective EGFR tyrosine
kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer
Res. 19:3508–3519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Arrieta O, Barrón F, Padilla MS,
Avilés-Salas A, Ramírez-Tirado LA, Arguelles Jiménez MJ, Vergara E,
Zatarain-Barrón ZL, Hernández-Pedro N, Cardona AF, et al: Effect of
metformin plus tyrosine kinase inhibitors compared with tyrosine
kinase inhibitors alone in patients with epidermal growth factor
receptor-mutated lung adenocarcinoma: A phase 2 randomized clinical
trial. JAMA Oncol. 5:e1925532019. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Chung C: Tyrosine kinase inhibitors for
epidermal growth factor receptor gene mutation-positive non-small
cell lung cancers: An update for recent advances in therapeutics. J
Oncol Pharm Pract. 22:461–476. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Bidkhori G, Moeini A and Masoudi-Nejad A:
Modeling of tumor progression in NSCLC and intrinsic resistance to
TKI in loss of PTEN expression. PLoS One. 7:e480042012. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H,
Li K, Chen H, Sun F, Yang Z, et al: Metformin sensitizes
EGFR-TKI-resistant human lung cancer cells in vitro and in vivo
through inhibition of IL-6 signaling and EMT reversal. Clin Cancer
Res. 20:2714–2726. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Momcilovic M, McMickle R, Abt E, Seki A,
Simko SA, Magyar C, Stout DB, Fishbein MC, Walser TC, Dubinett SM,
et al: Heightening energetic stress selectively targets
LKB1-deficient non-small cell lung cancers. Cancer Res.
75:4910–4922. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Della Corte CM, Ciaramella V, Di Mauro C,
Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E,
Troiani T, De Vita F, et al: Metformin increases antitumor activity
of MEK inhibitors through GLI1 downregulation in LKB1 positive
human NSCLC cancer cells. Oncotarget. 7:4265–4278. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Yeh HH, Lai WW, Chen HH, Liu HS and Su WC:
Autocrine IL-6-induced Stat3 activation contributes to the
pathogenesis of lung adenocarcinoma and malignant pleural effusion.
Oncogene. 25:4300–4309. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Pan YH, Jiao L, Lin CY, Lu CH, Li L, Chen
HY, Wang YB and He Y: Combined treatment with metformin and
gefitinib overcomes primary resistance to EGFR-TKIs with EGFR
mutation via targeting IGF-1R signaling pathway. Biologics.
12:75–86. 2018.PubMed/NCBI
|
|
135
|
Li L, Wang Y, Peng T, Zhang K, Lin C, Han
R, Lu C and He Y: Metformin restores crizotinib sensitivity in
crizotinib-resistant human lung cancer cells through inhibition of
IGF1-R signaling pathway. Oncotarget. 7:34442–34452. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Bland AR, Shrestha N, Bower RL, Rosengren
RJ and Ashton JC: The effect of metformin in EML(4)-ALK+ lung
cancer alone and in combination with crizotinib in cell and rodent
models. Biochem Pharmacol. 183:1143452021. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Chen H, Lin C, Peng T, Hu C, Lu C, Li L,
Wang Y, Han R, Feng M, Sun F, et al: Metformin reduces HGF-induced
resistance to alectinib via the inhibition of Gab1. Cell Death Dis.
11:1112020. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Isozaki H, Ichihara E, Takigawa N, Ohashi
K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Hotta K, Sakai K, et al:
Non-small cell lung cancer cells acquire resistance to the ALK
inhibitor alectinib by activating alternative receptor tyrosine
kinases. Cancer Res. 76:1506–1516. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Pan YH, Lin CY, Lu CH, Li L, Wang YB, Chen
HY and He Y: Metformin synergistically enhances the antitumor
activity of the third-generation EGFR-TKI CO-1686 in lung cancer
cells through suppressing NF-κB signaling. Clin Respir J.
12:2642–2652. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Mu CY, Huang JA, Chen Y, Chen C and Zhang
XG: High expression of PD-L1 in lung cancer may contribute to poor
prognosis and tumor cells immune escape through suppressing tumor
infiltrating dendritic cells maturation. Med Oncol. 28:682–688.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Miyazawa T, Marushima H, Saji H, Kojima K,
Hoshikawa M, Takagi M and Nakamura H: PD-L1 expression in
non-small-cell lung cancer including various adenocarcinoma
subtypes. Ann Thorac Cardiovasc Surg. 25:1–9. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Shen X, Zhao Y, Liu G, Zhou HL, Fan J,
Zhang L, Li YL, Wang Y, Liang J and Xu ZX: Upregulation of
programmed death ligand 1 by liver kinase B1 and its implication in
programmed death 1 blockade therapy in non-small cell lung cancer.
Life Sci. 256:1179232020. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Xia W, Qi X, Li M, Wu Y, Sun L, Fan X,
Yuan Y and Li J: Metformin promotes anticancer activity of NK cells
in a p38 MAPK dependent manner. Oncoimmunology. 10:19959992021.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Lee CK, Man J, Lord S, Cooper W, Links M,
Gebski V, Herbst RS, Gralla RJ, Mok T and Yang JC: Clinical and
molecular characteristics associated with survival among patients
treated with checkpoint inhibitors for advanced Non-small cell lung
carcinoma: A systematic review and Meta-analysis. JAMA Oncol.
4:210–216. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Kauffmann-Guerrero D, Tufman A, Kahnert K,
Bollmann BA, Reu S, Syunyaeva Z, Schneider C, Manapov F, Huber RM
and Golpon H: Response to checkpoint inhibition in Non-small cell
lung cancer with molecular driver alterations. Oncol Res Treat.
43:289–298. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Cinausero M, Laprovitera N, De Maglio G,
Gerratana L, Riefolo M, Macerelli M, Fiorentino M, Porcellini E,
Buoro V, Gelsomino F, et al: KRAS and ERBB-family genetic
alterations affect response to PD-1 inhibitors in metastatic
nonsquamous NSCLC. Ther Adv Med Oncol. 11:17588359198855402019.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Liu C, Zheng S, Jin R, Wang X, Wang F,
Zang R, Xu H, Lu Z, Huang J, Lei Y, et al: The superior efficacy of
anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung
cancer that correlates with an inflammatory phenotype and increased
immunogenicity. Cancer Lett. 470:95–105. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Calles A, Sholl LM, Rodig SJ, Pelton AK,
Hornick JL, Butaney M, Lydon C, Dahlberg SE, Oxnard GR, Jackman DM,
et al: Immunohistochemical Loss of LKB1 is a biomarker for more
aggressive biology in KRAS-mutant lung adenocarcinoma. Clin Cancer
Res. 21:2851–2860. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Biton J, Mansuet-Lupo A, Pécuchet N,
Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser
F, Leroy K, Goc J, et al: TP53, STK11, and EGFR mutations predict
tumor immune profile and the response to Anti-PD-1 in lung
adenocarcinoma. Clin Cancer Res. 24:5710–5723. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Rizvi H, Sanchez-Vega F, La K, Chatila W,
Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N,
et al: Molecular determinants of response to anti-programmed cell
death (PD)-1 and Anti-programmed Death-ligand 1 (PD-L1) blockade in
patients with Non-small-cell lung cancer profiled with targeted
Next-generation sequencing. J Clin Oncol. 36:633–641. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Skoulidis F, Goldberg ME, Greenawalt DM,
Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco
SE, Gay L, et al: STK11/LKB1 mutations and PD-1 inhibitor
resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov.
8:822–835. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Afzal MZ, Dragnev K, Sarwar T and Shirai
K: Clinical outcomes in Non-small-cell lung cancer patients
receiving concurrent metformin and immune checkpoint inhibitors.
Lung Cancer Manag. 8:LMT112019. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Kim Y, Vagia E, Viveiros P, Kang CY, Lee
JY, Gim G, Cho S, Choi H, Kim L, Park I, et al: Overcoming acquired
resistance to PD-1 inhibitor with the addition of metformin in
small cell lung cancer (SCLC). Cancer Immunol Immunother.
70:961–965. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Yendamuri S, Barbi J, Pabla S, Petrucci C,
Punnanitinont A, Nesline M, Glenn ST, Depietro P,
Papanicalou-Sengos A, Morrison C, et al: Body mass index influences
the salutary effects of metformin on survival after lobectomy for
stage I NSCLC. J Thorac Oncol. 14:2181–2187. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Tsakiridis T, Pond GR, Wright J, Ellis PM,
Ahmed N, Abdulkarim B, Roa W, Robinson A, Swaminath A, Okawara G,
et al: Metformin in combination with chemoradiotherapy in locally
advanced Non-small cell lung cancer: The OCOG-ALMERA randomized
clinical trial. JAMA Oncol. 7:1333–1341. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Syngelaki A, Nicolaides KH, Balani J, Hyer
S, Akolekar R, Kotecha R, Pastides A and Shehata H: Metformin
versus placebo in obese pregnant women without diabetes mellitus. N
Engl J Med. 374:434–443. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Okayasu S, Kitaichi K, Hori A, Suwa T,
Horikawa Y, Yamamoto M, Takeda J and Itoh Y: The evaluation of risk
factors associated with adverse drug reactions by metformin in type
2 diabetes mellitus. Biol Pharm Bull. 35:933–937. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Zhang HH and Guo XL: Combinational
strategies of metformin and chemotherapy in cancers. Cancer
Chemother Pharmacol. 78:13–26. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Mallik R and Chowdhury TA: Metformin in
cancer. Diabetes Res Clin Pract. 143:409–419. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Skuli SJ, Alomari S, Gaitsch H, Bakayoko
A, Skuli N and Tyler BM: Metformin and cancer, an ambiguanidous
relationship. Pharmaceuticals (Basel). 15:6262022. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Osama H, Sayed OM, Hussein RRS, Abdelrahim
M and A Elberry A: Design, optimization, characterization, and in
vivo evaluation of sterosomes as a carrier of metformin for
treatment of lung cancer. J Liposome Res. 30:150–162. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Goodwin J, Neugent ML, Lee SY, Choe JH,
Choi H, Jenkins DMR, Ruthenborg RJ, Robinson MW, Jeong JY, Wake M,
et al: The distinct metabolic phenotype of lung squamous cell
carcinoma defines selective vulnerability to glycolytic inhibition.
Nat Commun. 8:155032017. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Li C, Xue Y, Xi YR and Xie K: Progress in
the application and mechanism of metformin in treating Non-small
cell lung cancer. Oncol Lett. 13:2873–2880. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Chen N, Zhou YS, Wang LC and Huang JB:
Advances in metformin-based metabolic therapy for non-small cell
lung cancer (Review). Oncol Rep. 47:552022. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Arrieta O, Zatarain-Barrón ZL, Turcott JG,
Barrón F, Yendamuri S, Cardona AF and Rosell R: Association of BMI
with benefit of metformin plus epidermal growth factor
Receptor-tyrosine kinase inhibitors in patients with advanced lung
adenocarcinoma: A secondary analysis of a phase 2 randomized
clinical trial. JAMA Oncol. 8:477–479. 2022. View Article : Google Scholar : PubMed/NCBI
|
